MIAMI LAKES, FL--(Marketwired - Nov 21, 2013) - Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com) a consumer products and delivery technology company that is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, announced today an update on the introduction of Macular's Health's new MacuDrop™ AREDS II formula containing Fuse Science® technology at the American Academy of Ophthalmology Meeting.

As previously reported, Macular Health has partnered with Fuse Science® to develop new patent pending sublingual drop formulations to enhance treatment for Age-Related Macular Degeneration ("AMD"). AMD is a medical condition, which usually affects older adults and results in a loss of vision because of damage to the retina.

At the American Academy of Ophthalmology Meeting (AAO), November 16th-19th 2013, Macular Health showcased the MacuDrop™ AREDS II Formula.

"The introduction of the new MacuDrop™ technology was met with overwhelming domestic and international response," said Jeffrey McAnnally, President of Macular Health LLC. "We were very pleased with the response we received, especially from international physicians. Many of the doctors I spoke with personally felt like this was going to redefine the ocular nutrition market. Other physicians referred to it as 'a game changer'. The unique delivery method drove physicians to our booth. Many ophthalmologists felt the improvement in how you deliver the AREDS II formula could change the entire marketplace. We, as a company, are poised to redefine how ocular nutrition will be delivered in the future. It is our goal to have our new MacuDrop™ technology commercially available in January 2014.

"We've worked very hard over the past two years on the continued development of our proprietary technology and we are pleased by the response from the Ophthalmologists and the market to our AREDS II formula in partnership with Macular Health," said Jeanne Hebert, Fuse Science Sr. Vice President Marketing and Clinical Research. "We're experiencing strong interest in various formulations of our technology, including ocular health, hormone therapy, sports nutrition, pain management and other OTC and pharmaceutical applications globally. We anticipate further licensing opportunities in the near future."

About Age-Related Macular Degeneration
Macular degeneration is the leading cause of blindness in American adults. The condition, which is a breakdown of the macula of the eye, typically occurs during the aging process. Damage of the macula, caused by macular degeneration, increases the difficulty of seeing fine details clearly. Macular degeneration can make activities such as reading and threading a needle impossible. The ability to see both near and far is hindered by macular degeneration because damage to the macula causes blurriness and distortion of vision. There is no cure for macular degeneration, but there is hope of slowing vision loss with proper nutrition. For more information, visit www.macularhealth.com.

About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP), is an innovative consumer products and delivery technology company based in Miami Lakes, Florida. Fuse Science® holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. These rights include sublingual and transdermal delivery systems for bioactive agents that can, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is simply applied under the tongue. The Fuse Science® technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science® is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

For Fuse Science® news as it happens, follow @FuseScience on Twitter and Like "Fuse Science" on Facebook, www.facebook.com/FuseScience.

Get all Fuse Science® corporate updates sent directly to you; sign up for Fuse News Alerts in the Investor Relations section at www.fusescience.com.

For more information:
Fuse Science, Inc.
Investor Relations
Direct: (305) 503-3873, Ext. 2
Email: ir@fusescience.com